🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hansoh BioMedical R&D Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Hansoh BioMedical R&D Company as lead sponsor. Synced 26 Sep 2026
29Current trials
22Recruiting now
28Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hansoh BioMedical R&D Company is the lead sponsor of 29 current clinical trials in our China and USA registers. 22 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are HS-20093, HS-20089 and Bevacizumab. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting2276%
  • Not yet open621%
  • Active, closed13%

Trials by phase

  • Phase 11552%
  • Phase 2724%
  • Phase 3517%
  • Phase 2/313%
  • Phase 1/213%
01

Clinical trials sponsored by Hansoh BioMedical R&D Company

29 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: HS-20122
Phase 1 Recruiting 2025-04 China
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923 · ClinicalTrials.gov ↗ · Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Drug: HS-20093
Phase 1 Recruiting 2026-01 China
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06417008 · ClinicalTrials.gov ↗ · Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3 Recruiting 2024-05 China
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123 · ClinicalTrials.gov ↗ · Osteosarcoma, Sarcoma
Phase 2 Recruiting 2023-06 China
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2024-04 China
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
NCT06332170 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-04 China
HS-20117-2 Injection in Patients With Advanced Solid Tumors
NCT07775703 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2025-11 China
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379 · ClinicalTrials.gov ↗ · Solid Tumors
Phase 1 Recruiting 2025-02 USA, China
A Study of HS-20124 in Patients with Advanced Solid Tumors
NCT06763159 · ClinicalTrials.gov ↗ · Solid Cancer
Phase 1 Recruiting 2024-10 China
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
NCT07115446 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer
Phase 1 Recruiting 2025-08 China
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma
Drug: HS-20093
Phase 2 Recruiting 2023-12 China
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
NCT05942625 · ClinicalTrials.gov ↗ · IgA Nephropathy, Focal Segmental Glomerulosclerosis
Drug: HS-10390
Phase 1 Recruiting 2023-05 China
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
NCT07645222 · ClinicalTrials.gov ↗ · Lung Cancer
Phase 1 Recruiting 2026-06 China
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
NCT06621563 · ClinicalTrials.gov ↗ · Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
Phase 1 Recruiting 2024-12 China
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Drug: HS-20089
Phase 2 Recruiting 2023-12 China
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
NCT07186452 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2025-09 China
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)
Phase 1 Recruiting 2024-10 China
A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2025-05 China
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
NCT06112704 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Drug: HS-20093
Phase 2 Recruiting 2024-02 China
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
NCT07283367 · ClinicalTrials.gov ↗ · CRC
Phase 1/2 Recruiting 2025-12 China
ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Phase 3 Recruiting 2024-07 China
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06855069 · ClinicalTrials.gov ↗ · Ovarian Cancer
Phase 3 Recruiting 2025-03 China
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606 · ClinicalTrials.gov ↗ · Platinum-sensitive Recurrent Ovarian Cancer
Phase 3 Not yet open 2026-11 China
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
NCT06672393 · ClinicalTrials.gov ↗ · Psoriasis
Drug: HS-10374
Phase 3 Not yet open 2024-11 China
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
NCT05940116 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Solid Tumor
Drug: HS-20117
Phase 1 Not yet open 2023-07 China
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
NCT06635772 · ClinicalTrials.gov ↗ · Immunoglobulin a Nephropathy
Phase 2 Not yet open 2024-11 China
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT06594965 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Anemia, MDS
Phase 2 Not yet open 2024-10 China
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
NCT06926582 · ClinicalTrials.gov ↗ · Psoriasis
Drug: HS-10374
Phase 2 Not yet open 2025-04 China
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
NCT06935409 · ClinicalTrials.gov ↗ · Osteosarcoma
Phase 3 Active, closed 2025-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hansoh BioMedical R&D Company trials

28 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hansoh BioMedical R&D Company trials

30 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2922
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
Bristol-Myers Squibb5
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Bayer3
Vividion Therapeutics3
Multitude Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Hansoh BioMedical R&D Company trials

How many clinical trials does Hansoh BioMedical R&D Company sponsor?

Hansoh BioMedical R&D Company is the lead sponsor of 29 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hansoh BioMedical R&D Company trials recruiting?

Yes. 22 of its 29 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hansoh BioMedical R&D Company testing?

Its current trials name 28 drugs and biologicals as interventions. The most frequent are HS-20093 (9), HS-20089 (4), Bevacizumab (3), HS-20117 (3) and Adebrelimab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.